GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (NAS:GMAB) » Definitions » Construction In Progress

GMAB (Genmab AS) Construction In Progress : $0 Mil (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Genmab AS Construction In Progress?

Genmab AS's quarterly construction in progress increased from Sep. 2024 ($0 Mil) to Dec. 2024 ($14 Mil) but then declined from Dec. 2024 ($14 Mil) to Mar. 2025 ($0 Mil).

Genmab AS's annual construction in progress declined from Dec. 2022 ($34 Mil) to Dec. 2023 ($6 Mil) but then increased from Dec. 2023 ($6 Mil) to Dec. 2024 ($14 Mil).

Genmab AS Construction In Progress Historical Data

The historical data trend for Genmab AS's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Construction In Progress Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.31 7.92 33.54 5.79 14.37

Genmab AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 14.37 -

Genmab AS Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Genmab AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (NAS:GMAB) » Definitions » Construction In Progress
Comparable Companies
OCSE:ALK B OCSE:ZEAL OCSE:BAVA OCSE:GUBRA OCSE:PEG OCSE:STRAP VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270 SMMT RPRX XKRX:196170 INSM
Traded in Other Exchanges
GNMSF:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany GE91:Germany GE9:Germany GMAB:Austria
Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Website
https://www.genmab.com
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.